fludarabine

(redirected from Fludarabine phosphate)

fludarabine

 [floo-dar´ah-bēn]
an adenine analogue and purineantimetabolite that inhibits DNA synthesis; administered intravenously as the phosphate salt as an antineoplastic agent in the treatment of chronic lymphocytic leukemia.

fludarabine

/flu·dar·a·bine/ (floo-dar´ah-bēn) an adenine analogue and purine antimetabolite used as the phosphate salt as an antineoplastic in the treatment of chronic lymphocytic leukemia.

fludarabine

an antimetabolite used to treat neoplasia.
indications It is prescribed in the treatment of patients with B cell chronic lymphocytic leukemia and as salvage therapy for non-Hodgkin's lymphoma and acute leukemias.
contraindications It should not be given to patients who are pregnant or hypersensitive to this drug or its components. Patients should be closely observed for signs of hematologic and nonhematologic toxicity (e.g., edema, fatigue, myalgias).
adverse effects It is a potent antineoplastic agent with potentially significant side effects. The side effects most often reported include myelosuppression, fever and chills, nausea, and vomiting.

fludarabine

A CYTOTOXIC anti-cancer drug. A brand name is Fludara.
References in periodicals archive ?
Fludarabine 50mg injections fludarabine phosphate 50mg powder or solution for injection for i.
Its Bioniche Pharma unit was given FDA approval of its ANDA for fludarabine phosphate injection USR 25 mg/mL, packaged in 50 mg/2 mL single-dose vials.
M2 EQUITYBITES-October 5, 2010-Mylan Inc awarded approval for Fludarabine Phosphate Injection, USP(C)2010 M2 COMMUNICATIONS http://www.
M2 PHARMA-October 4, 2010-Mylan gains FDA nod for Fludarabine Phosphate Injection, USP(C)2010 M2 COMMUNICATIONS
Subsequently, the patient was started on fludarabine phosphate single-agent therapy and continued for 6 cycles to completion.
The FDA has granted approval of its ANDA for fludarabine phosphate injection, 25 mg/ml.
We describe a patient with B-CLL whose B cells expressed CD8, a predominantly T-cell marker also expressed in natural killer cells, and we propose that patients with this uncommon feature of B-CLL might have an increased sensitivity to fludarabine phosphate, a substance recently often used to treat patients with CLL.
In the fourth quarter of 2007, APP launched liquid and lyophilized Fludarabine Phosphate as well as four dosage forms of Epirubicin Hydrochloride Injection.
a privately-held oncology and autoimmune disease drug development company, today announced that its New Drug Application (NDA) for fludarabine phosphate oral tablets (oral fludarabine) was accepted for filing by the U.
a privately-held oncology and autoimmune disease drug development company, today announced that the FDA has granted Orphan Drug Designation to fludarabine phosphate oral tablets for the treatment of B-cell chronic lymphocytic leukemia.
In October 2007, the Company received tentative approval for Irinotecan Hydrochloride Injection and approvals for Epirubicin Hydrochloride Injection (in four dosage forms), liquid and lyophilized Fludarabine Phosphate.
The liquid version of fludarabine, which is the equivalent of fludarabine phosphate for injection marketed by Teva Parenteral Medicines, Inc.